Research shows weight loss surgery can help reduce the risk of severe liver problems for some patients with MASH.
In 2021, liver disease led to 2.7 million emergency department (ED) visits in the U.S., 2 million hospitalizations, and ...
Weight loss is a key effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), but these drugs may also provide liver ...
The tool reduces pathologist variability in liver biopsy assessment during trials of treatments for metabolic ...
EMA’s human medicines committee qualifies first AI tool to diagnose inflammatory liver disease in biopsy samples: Amsterdam, The Netherlands Saturday, March 22, 2025, 16:00 Hrs ...
AI-powered digital pathology specialist PathAI, based in Boston in the US, said that AIM-NASH AI Assist is designed to assist ...
Histoindex Pte Ltd. launched its laboratory-developed test for metabolic dysfunction-associated steatohepatitis (MASH), ...
PathAI, a global leader in AI-powered pathology, today announced that the European Medicines Agency (EMA) Committee for ...
Machine learning may help identify biomarkers and develop predictive models that could assist in the diagnosis of metabolic ...
HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the ...
HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the launch of their first Laboratory Developed Test (LDT) FibroSIGHTtm ? now ...
AZoLifeSciences on MSN16d
Study Explores the Physiological Role of Nwd1 Gene in MASH PathogenesisMetabolic dysfunction-associated steatohepatitis (MASH) is a liver disease that progresses without symptoms and is associated with significant global public health concerns.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback